Leerink Partners Downgrades Bristol-Myers Squibb to Market Perform, Lowers Price Target to $59

Leerink Partners analyst David Risinger has downgraded Bristol-Myers Squibb (NYSE: BMY) from Outperform to Market Perform. The price target for the stock has also been reduced from $73 to $59.